Scientists are in the race to discover more drugs for cancer treatment. Clay Siegall stands tall among the researchers who have managed to bring to fruition some of the best cancer therapies. He is the man behind Seattle Genetics, a biotech firm that does research on antibodies and converts them into cancer drugs. Founded nearly two decades ago, Seattle Genetics has continued to grow and is soon likely to attain the status of a pharmaceutical company.
Currently, the market value of the oncology company stands at about $10 billion, while the number of employees has surged to over 900, making Seattle Genetics the leading biotech company in Washington. Clay Siegall, the chairperson, president, CEO and co-founder of Seattle Genetics, says that they are focused on becoming giants in the oncology industry who are capable of supplying the market with a wide range of cancer drugs. The company’s long list of drugs on pipeline points out its commitment to this course.
In the quest to transform into a pharmaceutical company, Seattle Genetics has moved beyond drug development to making international marketing a central part of its operations. The past partnership with Takeda Oncology gave the company a chance to learn about the dynamics of marketing new drugs in the international market. Clay believes that with this experience, they will be able to navigate all the hurdles faced by new drugs in globe scenes. The increased attention on the global market saw the firm open offices in Switzerland, and this was followed by a $2 billion bid to acquire worldwide rights for commercialization of cancer drugs.
International marketing is perhaps the reason the sales of Seattle Genetics have increased by over 46 percent since 2014. In the same period, the stock price appreciated from $20 to $66.
About Clay Siegall
Clay Siegall is the co-founder of Seattle Genetics. He serves as president and CEO; additionally, he sits at the board of the company as the chairperson. Dr. Siegall has used his leadership skills to steer Seattle Genetics into becoming a premier biotech company. The approval of ADCETRIS by the U.S. Food and Drug Administration is one of the milestones the company has achieved under Siegall’s leadership.
Dr. Siegall also has played a pivotal role in raising massive capital for the operations of the company. Besides holding demanding roles at Seattle Genetics, Dr. Siegall, alongside Matthew Fust, was appointed to the board of Ultragenyx Pharmaceutical Inc. as directors.